Nexturastat A | HDAC6 Inhibitor | AmBeed-信号通路专用抑制剂

Nexturastat A {[allProObj[0].p_purity_real_show]}

货号：A293543

Nexturastat A是一种选择性的 HDAC6 抑制剂，IC50 为 5 nM。

Nexturastat A 化学结构
CAS号：1403783-31-2

Nexturastat A 3D分子结构
CAS号：1403783-31-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-A, IC50: 16 nM HD1-B, IC50: 7.5 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	EGFR,HER2	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													99%
Panobinostat			++++ HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											p53,NF-κB	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			99%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			97%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Nexturastat A 生物活性

靶点

HDAC6

HDAC6, IC50:5 nM

描述

Histone deacetylases (HDACs) participate in the control of cellular biological processes via specificly removing acetyl groups on lysine residues in histones and non-histone proteins. The isoform of HDAC6 is orientated in the cytoplasm and mainly interacts with non-histone proteins. It plays a central role in microtubule-dependent cell motility via deacetylation of tubulin. In addition to its protein deacetylase activity, HDAC6 plays a key role in the degradation of misfolded proteins. Nexturastat A is a HDAC6 selective inhibitor with IC₅₀ of 5.02nM, while the IC₅₀s of it against HDAC1, 2, 3, 4, 5, 7, 8, 9, 10, 11 were 3.02μM, 6.92μM, 6.68μM, 9.39μM, 11.7μM, 4.46μM, 0.95μM, 6.72μM, 7.57μM and 5.14μM, respectively^[3]. Treatment of B16 cells with Nexturastat A at doses ranging from 1nM to 10000nM concentration dependently increased acetyl-tubulin levels^[3]. 10μM, 20μM , 30μM and 40μM Nexturastat A dose-dependently impaired the viability of multiple myeloma PRMI-8226 and U266 cell lines. 48h treatment of Nexturastat A at the concentration of 40μM induced apoptosis in RPMI-8226 and U266 cells^[4]. In SM1 murine melanoma tumor model established in C57BL/6 mice, Nexturastat A was administrated 5 times a week at the dose of 15mg/kg, or in combination of anti-PD-1 for 25 days. At day25, the tumor volume of the combination group, Nexturastat A group, anti-PD-1 group and control group were 257.3mm³, 750.1 mm³, 1030 mm³ and 2034 mm³, respectively^[5].

Nexturastat A 细胞实验

Cell Line WM164 human melanoma cells B16 melanoma cells SM1 melanoma cells THP-1-derived macrophages A31A7 macrophages Bone marrow-derived macrophages (BMDMs) Mouse peritoneal elicited macrophage (PEM) SM1 melanoma cells RPMI-8226/BTZ100 cells U266 cells RPMI-8226 cells OVSAHO Kuramochi HEY CaOV3 A2780 HeLa cells HT1080 cells HEK-293 cells BT474 SKBR3	Concentration	Treated Time	Description	References
WM164 human melanoma cells	5 µM	24 hours	HDAC6 knockdown downregulated CD47 expression and prevented IFNγ-driven CD47 upregulation.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
B16 melanoma cells	5 µM	24 hours	Nexturastat A repressed IFNγ-driven Cd47 upregulation.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
SM1 melanoma cells	5 µM	24 hours	Nexturastat A repressed IFNγ-driven Cd47 upregulation.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
THP-1-derived macrophages	5 µM	24 hours	Nexturastat A significantly upregulated M1-associated markers NOS2, CD86, and IL1B and downregulated M2-associated markers MRC1 and CD209.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
A31A7 macrophages	5 µM	24 hours	Nexturastat A significantly upregulated surface expression of M1-associated markers Cd80 and H2 and downregulated surface expression of M2-associated marker Cd206.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
Bone marrow-derived macrophages (BMDMs)	5 µM	24 hours	Nexturastat A significantly upregulated M1-associated markers Nos2 and Cd80 and downregulated M2-associated markers Arg1 and Mrc1 at the transcriptional level.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
Mouse peritoneal elicited macrophage (PEM)	5 µM	24 hours	To evaluate the effect of Nexturastat A on macrophage polarization, results showed that NextA reduced the expression of M2 marker CD206 and increased the M1 phenotype.	Sci Rep. 2019 Apr 16;9(1):6136.
SM1 melanoma cells	2.5 and 5 µM	24 hours	To evaluate the effect of Nexturastat A on PD-L1 expression, results showed that NextA neutralized the anti-PD1 antibody-mediated upregulation of IFNγ on PD-L1 production.	Sci Rep. 2019 Apr 16;9(1):6136.
RPMI-8226/BTZ100 cells	20 µM	48 hours	To evaluate the effect of NexA on BTZ-resistant cell viability, results showed that NexA remarkably suppressed the viability of RPMI-8226/BTZ100 cells.	Biosci Rep. 2019 Mar 22;39(3):BSR20181916.
U266 cells	30 µM	48 hours	To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines.	Biosci Rep. 2019 Mar 22;39(3):BSR20181916.
RPMI-8226 cells	30 µM	48 hours	To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines.	Biosci Rep. 2019 Mar 22;39(3):BSR20181916.
OVSAHO	12500 nM	48 hours preincubation followed by 72 hours incubation	Nexturastat A increased cisplatin potency in OVSAHO cells, with IC50 values in the micromolar range.	Int J Mol Sci. 2019 Jun 22;20(12):3052.
Kuramochi	5000 nM	48 hours preincubation followed by 72 hours incubation	Nexturastat A increased cisplatin potency in Kuramochi cells, with IC50 values in the micromolar range.	Int J Mol Sci. 2019 Jun 22;20(12):3052.
HEY	5000 nM	48 hours preincubation followed by 72 hours incubation	Nexturastat A increased cisplatin potency in HEY cells, with IC50 values in the micromolar range.	Int J Mol Sci. 2019 Jun 22;20(12):3052.
CaOV3	7500 nM	48 hours preincubation followed by 72 hours incubation	Nexturastat A increased cisplatin potency in CaOV3 cells, with IC50 values in the micromolar range.	Int J Mol Sci. 2019 Jun 22;20(12):3052.
A2780	7500 nM	48 hours preincubation followed by 72 hours incubation	Nexturastat A increased cisplatin potency in A2780 cells, with IC50 values in the micromolar range.	Int J Mol Sci. 2019 Jun 22;20(12):3052.
HeLa cells	2.5 µM	72 hours	Nexturastat A increased BE3-mediated gene editing efficiency in HeLa cells, with an average improvement of 4.90-fold.	Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.
HT1080 cells	2.5 µM	72 hours	Nexturastat A significantly improved BE3-mediated gene editing efficiency in HT1080 cells, with an average improvement of 7.96-fold.	Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.
HEK-293 cells	2.5 µM	72 hours	Nexturastat A increased BE3-mediated gene editing efficiency, with an average improvement of 3.46-fold.	Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.
BT474	0.37 nM to 100 µM	72 hours	Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines.	Cancers (Basel). 2024 Nov 6;16(22):3752.
SKBR3	0.37 nM to 100 µM	72 hours	Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines, with the lowest IC50 in SKBR3 clones.	Cancers (Basel). 2024 Nov 6;16(22):3752.

Cell Line

Concentration

Treated Time

Description

References

WM164 human melanoma cells

5 µM

24 hours

HDAC6 knockdown downregulated CD47 expression and prevented IFNγ-driven CD47 upregulation.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

B16 melanoma cells

5 µM

24 hours

Nexturastat A repressed IFNγ-driven Cd47 upregulation.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

SM1 melanoma cells

5 µM

24 hours

Nexturastat A repressed IFNγ-driven Cd47 upregulation.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

THP-1-derived macrophages

5 µM

24 hours

Nexturastat A significantly upregulated M1-associated markers NOS2, CD86, and IL1B and downregulated M2-associated markers MRC1 and CD209.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

A31A7 macrophages

5 µM

24 hours

Nexturastat A significantly upregulated surface expression of M1-associated markers Cd80 and H2 and downregulated surface expression of M2-associated marker Cd206.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

Bone marrow-derived macrophages (BMDMs)

5 µM

24 hours

Nexturastat A significantly upregulated M1-associated markers Nos2 and Cd80 and downregulated M2-associated markers Arg1 and Mrc1 at the transcriptional level.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

Mouse peritoneal elicited macrophage (PEM)

5 µM

24 hours

To evaluate the effect of Nexturastat A on macrophage polarization, results showed that NextA reduced the expression of M2 marker CD206 and increased the M1 phenotype.

Sci Rep. 2019 Apr 16;9(1):6136.

SM1 melanoma cells

2.5 and 5 µM

24 hours

To evaluate the effect of Nexturastat A on PD-L1 expression, results showed that NextA neutralized the anti-PD1 antibody-mediated upregulation of IFNγ on PD-L1 production.

Sci Rep. 2019 Apr 16;9(1):6136.

RPMI-8226/BTZ100 cells

20 µM

48 hours

To evaluate the effect of NexA on BTZ-resistant cell viability, results showed that NexA remarkably suppressed the viability of RPMI-8226/BTZ100 cells.

Biosci Rep. 2019 Mar 22;39(3):BSR20181916.

U266 cells

30 µM

48 hours

To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines.

Biosci Rep. 2019 Mar 22;39(3):BSR20181916.

RPMI-8226 cells

30 µM

48 hours

To evaluate the effect of NexA on cell viability, results showed that NexA dose-dependently impaired the viability of the two cell lines.

Biosci Rep. 2019 Mar 22;39(3):BSR20181916.

OVSAHO

12500 nM

48 hours preincubation followed by 72 hours incubation

Nexturastat A increased cisplatin potency in OVSAHO cells, with IC50 values in the micromolar range.

Int J Mol Sci. 2019 Jun 22;20(12):3052.

Kuramochi

5000 nM

48 hours preincubation followed by 72 hours incubation

Nexturastat A increased cisplatin potency in Kuramochi cells, with IC50 values in the micromolar range.

Int J Mol Sci. 2019 Jun 22;20(12):3052.

HEY

5000 nM

48 hours preincubation followed by 72 hours incubation

Nexturastat A increased cisplatin potency in HEY cells, with IC50 values in the micromolar range.

Int J Mol Sci. 2019 Jun 22;20(12):3052.

CaOV3

7500 nM

48 hours preincubation followed by 72 hours incubation

Nexturastat A increased cisplatin potency in CaOV3 cells, with IC50 values in the micromolar range.

Int J Mol Sci. 2019 Jun 22;20(12):3052.

A2780

7500 nM

48 hours preincubation followed by 72 hours incubation

Nexturastat A increased cisplatin potency in A2780 cells, with IC50 values in the micromolar range.

Int J Mol Sci. 2019 Jun 22;20(12):3052.

HeLa cells

2.5 µM

72 hours

Nexturastat A increased BE3-mediated gene editing efficiency in HeLa cells, with an average improvement of 4.90-fold.

Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.

HT1080 cells

2.5 µM

72 hours

Nexturastat A significantly improved BE3-mediated gene editing efficiency in HT1080 cells, with an average improvement of 7.96-fold.

Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.

HEK-293 cells

2.5 µM

72 hours

Nexturastat A increased BE3-mediated gene editing efficiency, with an average improvement of 3.46-fold.

Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.

BT474

0.37 nM to 100 µM

72 hours

Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines.

Cancers (Basel). 2024 Nov 6;16(22):3752.

SKBR3

0.37 nM to 100 µM

72 hours

Evaluate the cytotoxic effect of Nexturastat A on HER2+ breast cancer cells, showing that NextA was effective in both SKBR3 and BT474 cell lines, with the lowest IC50 in SKBR3 clones.

Cancers (Basel). 2024 Nov 6;16(22):3752.

Nexturastat A 动物实验

Species Mice C57BL/6 mice C57BL/6 mice Mice	Animal Model Oct4-eGFP mice SM1 melanoma model SM1 melanoma model Listeria infection model	Administration	Dosage	Frequency	Description	References
Mice	Oct4-eGFP mice	Added to embryo culture medium	0.5 µM	24 hours	Nexturastat A significantly improved BE3-mediated gene editing efficiency, with a 1.57-fold improvement in embryos.	Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.
C57BL/6 mice	SM1 melanoma model	Subcutaneous injection	15 mg/kg	5 days a week for 25 days	To evaluate the effect of Nexturastat A in combination with anti-PD-1 antibody, results showed that the combination significantly reduced tumor growth and enhanced immune cell infiltration.	Sci Rep. 2019 Apr 16;9(1):6136.
C57BL/6 mice	SM1 melanoma model	Intraperitoneally	20 mg/kg	Every other day until the end of the study	The combination of Nexturastat A and anti-CD47 significantly decreased tumor growth, increased immune cell infiltration in the tumor microenvironment (TME), and modulated macrophage and natural killer (NK) cell populations.	J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.
Mice	Listeria infection model	Intraperitoneal injection	3 mg/kg	5 days post infection	Reduced Listeria burdens, increased Th1 cell numbers	Cell Death Differ. 2022 Nov;29(11):2303-2315

Species

Mice C57BL/6 mice C57BL/6 mice Mice

Animal Model

Oct4-eGFP mice SM1 melanoma model SM1 melanoma model Listeria infection model

Administration

Dosage

Frequency

Description

References

Mice

Oct4-eGFP mice

Added to embryo culture medium

0.5 µM

24 hours

Nexturastat A significantly improved BE3-mediated gene editing efficiency, with a 1.57-fold improvement in embryos.

Nucleic Acids Res. 2021 Sep 7;49(15):8974-8986.

C57BL/6 mice

SM1 melanoma model

Subcutaneous injection

15 mg/kg

5 days a week for 25 days

To evaluate the effect of Nexturastat A in combination with anti-PD-1 antibody, results showed that the combination significantly reduced tumor growth and enhanced immune cell infiltration.

Sci Rep. 2019 Apr 16;9(1):6136.

C57BL/6 mice

SM1 melanoma model

Intraperitoneally

20 mg/kg

Every other day until the end of the study

The combination of Nexturastat A and anti-CD47 significantly decreased tumor growth, increased immune cell infiltration in the tumor microenvironment (TME), and modulated macrophage and natural killer (NK) cell populations.

J Exp Clin Cancer Res. 2024 Feb 27;43(1):60.

Mice

Listeria infection model

Intraperitoneal injection

3 mg/kg

5 days post infection

Reduced Listeria burdens, increased Th1 cell numbers

Cell Death Differ. 2022 Nov;29(11):2303-2315

Nexturastat A 参考文献

Nexturastat A 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.93mL

0.59mL

0.29mL

14.65mL

2.93mL

1.46mL

29.29mL

5.86mL

2.93mL

Nexturastat A 技术信息

CAS号	1403783-31-2
分子式	C₁₉H₂₃N₃O₃
分子量	341.4
SMILES Code	O=C(NO)C1=CC=C(CN(CCCC)C(NC2=CC=CC=C2)=O)C=C1
MDL No.	MFCD28099804

别名
运输	蓝冰
InChI Key	JZWXMCPARMXZQV-UHFFFAOYSA-N
Pubchem ID	71462653

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

细胞实验：

DMSO: 55 mg/mL(161.1 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

方案三

Nexturastat A {[allProObj[0].p_purity_real_show]}

Nexturastat A 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Nexturastat A 质控信息

Nexturastat A 生物活性

Nexturastat A 细胞实验

Nexturastat A 动物实验

Nexturastat A 参考文献

Nexturastat A 实验方案

Nexturastat A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Nexturastat A {[allProObj[0].p_purity_real_show]}

Nexturastat A 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Nexturastat A 质控信息

Nexturastat A 生物活性

Nexturastat A 细胞实验

Nexturastat A 动物实验

Nexturastat A 参考文献

Nexturastat A 实验方案

Nexturastat A 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Nexturastat A 纯度/质量文件产品仅供科研